PBLA (Panbela Therapeutics) Forward Dividend Yield %: 0.00% (As of Jul. 01, 2026)


What is Panbela Therapeutics Forward Dividend Yield %?

Panbela Therapeutics PBLA +2,400.00% Forward Dividend Yield % is 0.00% as of Jul. 01, 2026.

As of today (2026-07-01), the Forward Annual Dividend Yield of Panbela Therapeutics is 0.00%.

As of today (2026-07-01), the Trailing Annual Dividend Yield of Panbela Therapeutics is 0.00%.

PBLA's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.45
* Ranked among companies with meaningful Forward Dividend Yield % only.

Panbela Therapeutics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Panbela Therapeutics  (OTCPK:PBLA) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Panbela Therapeutics Forward Dividend Yield % Related Terms

PBLA vs VINC, OMGAQ, ENDV: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Panbela Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panbela Therapeutics Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's Forward Dividend Yield % falls into.


Panbela Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Panbela Therapeutics (PBLA) has a Forward Dividend Yield % of 0.00% as of Jul. 01, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Panbela Therapeutics and its competitors.
Is Panbela Therapeutics' Forward Dividend Yield % too high?
Panbela Therapeutics' current Forward Dividend Yield % is 0.00%.
How does Panbela Therapeutics' Forward Dividend Yield % compare to VINC and OMGAQ?
Panbela Therapeutics' Forward Dividend Yield % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Forward Dividend Yield % is 1.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.45, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Panbela Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panbela Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panbela Therapeutics stock overvalued right now?
Panbela Therapeutics (PBLA) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Panbela Therapeutics (PBLA), the current Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Panbela Therapeutics Business Description

Address 712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.